These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31911024)

  • 21. Motivations for new psychoactive substance use among regular psychostimulant users in Australia.
    Sutherland R; Bruno R; Peacock A; Lenton S; Matthews A; Salom C; Dietze P; Butler K; Burns L; Barratt MJ
    Int J Drug Policy; 2017 May; 43():23-32. PubMed ID: 28161577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel psychoactive substance use among treatment-seeking opiate users: The role of life events and psychiatric symptoms.
    Kapitány-Fövény M; Farkas J; Pataki PA; Kiss A; Horváth J; Urbán R; Demetrovics Z
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28618002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Typology of new psychoactive substance use among the general Australian population.
    Sutherland R; Peacock A; Roxburgh A; Barratt MJ; Burns L; Bruno R
    Drug Alcohol Depend; 2018 Jul; 188():126-134. PubMed ID: 29775956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of Novel Psychoactive Substance (NPS) Use in Patients Admitted to Drug Detoxification Treatment.
    Specka M; Kuhlmann T; Sawazki J; Bonnet U; Steinert R; Cybulska-Rycicki M; Eich H; Zeiske B; Niedersteberg A; Schaaf L; Scherbaum N
    Front Psychiatry; 2020; 11():569. PubMed ID: 32733288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting.
    Palamar JJ; Martins SS; Su MK; Ompad DC
    Drug Alcohol Depend; 2015 Nov; 156():112-119. PubMed ID: 26377051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. "Someone Else's Problem": New Psychoactive Substances in the Online Hungarian Media.
    Kassai S; Rácz J; Nagy A; Bíbók T; Galambvári É; Kilián C; Gyarmathy VA
    J Psychoactive Drugs; 2017; 49(1):47-51. PubMed ID: 28010181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intended and unintended use of cathinone mixtures.
    Guirguis A; Corkery JM; Stair JL; Kirton SB; Zloh M; Schifano F
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28657191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution.
    Banister SD; Connor M
    Handb Exp Pharmacol; 2018; 252():191-226. PubMed ID: 30105473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of illicit, licit, and designer drugs in the traffic in Hungary.
    Institóris L; Hidvégi E; Dobos A; Sija É; Kereszty ÉM; Tajti LB; Somogyi GP; Varga T
    Forensic Sci Int; 2017 Jun; 275():234-241. PubMed ID: 28412575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suspected synthetic cannabinoid receptor agonist intoxication: Does analysis of samples reflect the presence of suspected agents?
    Tebo C; Mazer-Amirshahi M; DeGeorge L; Gelfand B; Leak C; Tolliver S; Sauter D
    Am J Emerg Med; 2019 Oct; 37(10):1846-1849. PubMed ID: 30595429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel psychoactive substances (NPS) - knowledge and expe riences of drug users from Hungary, Poland, the UK and the USA.
    Pisarska A; Deluca P; Demetrovics Z; Moskalewicz J; ReDNet G
    Neuropsychopharmacol Hung; 2019 Dec; 21(4):152-163. PubMed ID: 32015192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidemiology and clinical features of toxicity following recreational use of synthetic cannabinoid receptor agonists: a report from the United Kingdom National Poisons Information Service.
    Waugh J; Najafi J; Hawkins L; Hill SL; Eddleston M; Vale JA; Thompson JP; Thomas SH
    Clin Toxicol (Phila); 2016 Jul; 54(6):512-8. PubMed ID: 27091041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterizing Trends in Synthetic Cannabinoid Receptor Agonist Use from Patient Clinical Evaluations during Medical Toxicology Consultation.
    Tebo C; Mazer-Amirshahi M; Wax P; Campleman S; Boyer E; Brent J; Sheth A; Daniuaityte R; Carlson R
    J Psychoactive Drugs; 2021; 53(3):207-214. PubMed ID: 33225872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characteristics of psychiatric inpatients diagnosed with mental and behavioral disorders caused by psychoactive substances (F11-19 block), with a focus on NPS and psychiatric co-morbidities.
    Engelgardt P; Krzyżanowski M; Piotrowski P; Borkowska-Sztachańska M; Wasilewska A; Kowalkowski T
    Int J Occup Med Environ Health; 2020 Mar; 33(2):125-136. PubMed ID: 31942874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A transnational perspective on the evolution of the synthetic cannabinoid receptor agonists market: Comparing prison and general populations.
    Norman C; Halter S; Haschimi B; Acreman D; Smith J; Krotulski AJ; Mohr ALA; Logan BK; NicDaéid N; Auwärter V; McKenzie C
    Drug Test Anal; 2021 Apr; 13(4):841-852. PubMed ID: 33463894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lifetime prevalence of novel psychoactive substances use among adults in the USA: Sociodemographic, mental health and illicit drug use correlates. Evidence from a population-based survey 2007-2014.
    Neicun J; Yang JC; Shih H; Nadella P; van Kessel R; Negri A; Czabanowska K; Brayne C; Roman-Urrestarazu A
    PLoS One; 2020; 15(10):e0241056. PubMed ID: 33125395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New psychoactive substance use among regular psychostimulant users in Australia, 2010-2015.
    Sutherland R; Peacock A; Whittaker E; Roxburgh A; Lenton S; Matthews A; Butler K; Nelson M; Burns L; Bruno R
    Drug Alcohol Depend; 2016 Apr; 161():110-8. PubMed ID: 26880592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of the UK Psychoactive Substances Act on awareness, use, experiences and knowledge of potential associated health risks of novel psychoactive substances.
    Deligianni E; Daniel OJ; Corkery JM; Schifano F; Lione LA
    Br J Clin Pharmacol; 2020 Mar; 86(3):505-516. PubMed ID: 31495968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5F-PY-PICA, 5F-PY-PINACA, and their analogs.
    Banister SD; Kevin RC; Martin L; Adams A; Macdonald C; Manning JJ; Boyd R; Cunningham M; Stevens MY; McGregor IS; Glass M; Connor M; Gerona RR
    Drug Test Anal; 2019 Jul; 11(7):976-989. PubMed ID: 30838752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New psychoactive substances (NPS) on cryptomarket fora: An exploratory study of characteristics of forum activity between NPS buyers and vendors.
    Van Hout MC; Hearne E
    Int J Drug Policy; 2017 Feb; 40():102-110. PubMed ID: 28027812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.